» Articles » PMID: 31938179

Rapid Diagnosis of Cisplatin-sensitive and Resistant Cervical Squamous Cell Carcinomas by Reverse Transcription Loop-mediated Isothermal Amplification

Overview
Specialty Pathology
Date 2020 Jan 16
PMID 31938179
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Cisplatin is a widely used platinum anticancer drug in cervical cancer chemotherapy; however, its use is limited by the development of drug resistance, which is often rationalized via effects on cellular uptake. Human copper transporter 1 (hCTR1) was proven as crucial regulator for cellular platinum uptake in cancer cells and improving effect of cisplatin treatment. Thus, methods to detect expression of hCTR1 in patients in biopsy specimens with certain rapidity and accuracy are essential to evaluate platinum drug sensitivity and perform further individualized treatment. In this study, a total of 46 normal cervical and primary cervical squamous cell carcinoma tissues were collected and tested by reverse transcription loop-mediated isothermal amplification (RT-LAMP) analysis targeted hCTR1 mRNA. Sensitivity and specificity of RT-LAMP results were calculated and compared to immunohistochemical (IHC) examination. Overexpression of hCTR1 RNA was detected in 12 samples using RT-LAMP within 45 minutes reaction, which indicated positivity with cisplatin resistance. This new technique is suggested to be alternative for rapid diagnosis of cisplatin sensitive patients whose hCTR1 is prevalent.

Citing Articles

Enzyme-Assisted Nucleic Acid Amplification in Molecular Diagnosis: A Review.

Wang M, Liu H, Ren J, Huang Y, Deng Y, Liu Y Biosensors (Basel). 2023; 13(2).

PMID: 36831926 PMC: 9953907. DOI: 10.3390/bios13020160.

References
1.
Muto Y, Matubara H, Tanizawa T, Nabeya Y, Kawahira H, Akai T . Rapid diagnosis of micrometastasis of gastric cancer using reverse transcription loop-mediated isothermal amplification. Oncol Rep. 2011; 26(4):789-94. DOI: 10.3892/or.2011.1389. View

2.
Ishida S, McCormick F, Smith-McCune K, Hanahan D . Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010; 17(6):574-83. PMC: 2902369. DOI: 10.1016/j.ccr.2010.04.011. View

3.
Liang Z, Stockton D, Savaraj N, Kuo M . Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol. 2009; 76(4):843-53. PMC: 2769054. DOI: 10.1124/mol.109.056416. View

4.
Go R, Adjei A . Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17(1):409-22. DOI: 10.1200/JCO.1999.17.1.409. View

5.
Fu S, Naing A, Fu C, Kuo M, Kurzrock R . Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012; 11(6):1221-5. PMC: 3667596. DOI: 10.1158/1535-7163.MCT-11-0864. View